A multi-centre general practice study evaluating the efficacy and tolerance of ibuprofen in common painful conditions

An open, multi-centre study in general practice was carried out in 1842 patients presenting with non-serious painful conditions to assess the effectiveness and tolerance of ibuprofen. Patients received daily doses ranging from 400 mg to 2400 mg for up to 1 month; most took between 1200 mg and 1600 m...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 4(1984), 1 vom: 15., Seite 9-12
1. Verfasser: Benvenuti, C (VerfasserIn)
Weitere Verfasser: Beretta, A, Longoni, A, Pickvance, N J
Format: Aufsatz
Sprache:English
Veröffentlicht: 1984
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Journal Article Suppositories Ibuprofen WK2XYI10QM
Beschreibung
Zusammenfassung:An open, multi-centre study in general practice was carried out in 1842 patients presenting with non-serious painful conditions to assess the effectiveness and tolerance of ibuprofen. Patients received daily doses ranging from 400 mg to 2400 mg for up to 1 month; most took between 1200 mg and 1600 mg per day for about 1 week. Assessments of pain severity on a visual analogue scale showed that 82% of patients with moderate to severe pain derived benefit from treatment, the analgesic effect of a dose often lasting up to 6 hours. The best response was seen in patients with dysmenorrhoea and dental pain, and although headache was less responsive than other painful conditions the overall rate of positive results for this diagnosis reached 75% in the opinion of both physicians and patients. Approximately 14% of patients reported side-effects, mostly gastro-intestinal with abdominal pain predominating
Beschreibung:Date Completed 04.01.1985
Date Revised 17.03.2022
published: Print
Citation Status MEDLINE